Jacobio, a Beijing Biopharma, Raises $174 Million in Hong Kong IPO
publication date: Dec 21, 2020
Jacobio of Beijing raised $174 million in a Hong Kong IPO to develop its portfolio of 12 novel drugs. Formed five years ago, Jacobio differs from most of its competition because, so far, it has developed all of its candidates in house, though its website says the company hopes to be a China partner for foreign biopharmas. It also works only on molecules that have first-in-class potential. In June, the company out-licensed rights for its two lead candidates, both of them allosteric SHP2 antibodies, to AbbVie. More details....
Stock Symbol: (NYSE: ABBV)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.